Solid Biosciences (SLDB) Gains from Investment Securities (2018 - 2026)
Solid Biosciences' (SLDB) quarterly Gains from Investment Securities came in at $3633.0 in Q1 2026, down 83.49% year-on-year from $22000.0 in Q1 2025, and down 95.73% quarter-over-quarter from $85000.0 in Q4 2025.
Solid Biosciences (SLDB) Gains from Investment Securities (2018 - 2026) Analysis & Trends
Solid Biosciences has disclosed Gains from Investment Securities across 9 years of filings, most recently posting $3633.0 for Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $3633.0, down 83.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $3633.0 (up 101.03% YoY), and the FY2025 annual result was $4.4 million, up 49.53% from the prior year.
- Gains from Investment Securities came in at $3633.0 for Q1 2026 at Solid Biosciences, down from $85000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $4.4 million in Q3 2025 to a low of -$374000.0 in Q4 2023.
- The 5-year median for Gains from Investment Securities is $174738.0 (2022), against an average of $658675.4.
- Across the five-year window, Gains from Investment Securities plunged 96.37% in 2022 and jumped 10222.76% in 2023, its largest moves.
- Solid Biosciences' Gains from Investment Securities stood at $8380.0 in 2022, then plunged by 4563.01% to -$374000.0 in 2023, then soared by 99.47% to -$2000.0 in 2024, then soared by 4350.0% to $85000.0 in 2025, then sank by 95.73% to $3633.0 in 2026.
- The last three Gains from Investment Securities figures came in at $3633.0 (Q1 2026), $85000.0 (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Solid Biosciences | 789.54 Mn | 408.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,633.00 |
| Mar 31, 2026 | 3,633.00 |
| Dec 31, 2025 | 85,000.00 |
| Dec 31, 2025 | 85,000.00 |
| Sep 30, 2025 | 4.38 Mn |
| Sep 30, 2025 | 4.38 Mn |
| Jun 30, 2025 | 103,882.00 |
| Jun 30, 2025 | 103,882.00 |
| Mar 31, 2025 | 22,000.00 |
| Mar 31, 2025 | 22,000.00 |
| Dec 31, 2024 | -2,000.00 |
| Dec 31, 2024 | -2,000.00 |
| Sep 30, 2024 | 2.94 Mn |
| Sep 30, 2024 | 2.94 Mn |
| Jun 30, 2024 | 421,148.00 |
| Jun 30, 2024 | 421,148.00 |
| Mar 31, 2024 | 601,402.00 |
| Mar 31, 2024 | 601,402.00 |
| Dec 31, 2023 | -374,000.00 |
| Dec 31, 2023 | -374,000.00 |